Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study |
| |
Authors: | D. Caputo M. Cartillone C. Cascone D. Pozzi L. Digiacomo S. Palchetti G. Caracciolo R. Coppola |
| |
Affiliation: | 1. Department of Surgery, University Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128, Rome, Italy;2. Department ?of? Molecular? Medicine, ‘Sapienza’?University?of Rome, Viale Regina Elena 291, 00161, Rome, Italy;3. Istituti Fisioterapici? Ospitalieri, Istituto Regina Elena, Via Elio ?Chianesi?53, 00144, Rome, Italy |
| |
Abstract: | BackgroundPancreatic ductal adenocarcinoma (PDAC) early diagnosis is? crucial ?and new, cheap and user-friendly techniques for biomarker identification? are ?needed. “Protein corona” (PC) is emerging a new bio-interface potentially useful in tumor early diagnosis. In a previous investigation, we showed that relevant differences between the ?protein patterns of? PCs formed on lipid NPs after exposure to PDAC and non-cancer plasma? samples exist. To extend that research, We performed this pilot study to investigate the effect of PDAC tumor size and distant metastases on PC composition.MethodsTwenty PDACs were clinically staged according to the UICC TNM staging system 8?t?h?Edition. Collected plasma samples were let to interact with lipid NPs; resulting PCs were characterized by SDS-PAGE. To properly evaluate changes in the PC, the protein intensity profiles were reduced to four regions of molecular weight: < 25?kDa, 25–50?kDa, 50–120?kDa, > 120?kDa.?ResultsData analysis allowed to?distinguish T1-T2 cases from T3 and?above all from?metastatic ones (p?0.05). Discrimination power was particularly due to a subset of plasma proteins with molecular ?weight comprised between 25-50?kDa ?and 50–120?kDa.ConclusionsPC composition is critically influenced by tumor size and presence of distant metastases in PDAC. If our findings will be further confirmed, we envision that future developments of cheap and user-friendly PC-based tools will allow to improve the accuracy of PDAC clinical staging, identifying among resectable ?PDACs with potentially better prognosis (i.e. T1 and T2) those?at higher risk of occult distant metastases. |
| |
Keywords: | Biomarkers for pancreatic ductal adenocarcinoma Nanotechnology Pancreatic adenocarcinoma clinical stage Protein corona Pancreatic ductal adenocarcinoma |
本文献已被 ScienceDirect 等数据库收录! |
|